In a notable decision, the Federal Circuit has upheld Actavis’ deduction of $12 million in litigation costs incurred in the process of obtaining approval for selling generic versions of birth control and other drugs. The court’s ruling affirms the previous judgment of the U.S. Court of Federal Claims, which recognized these legal expenditures as ordinary business expenses. This outcome reinforces the notion that expenses associated with legal defenses in the course of business operations may be treated as deductible.
The ruling, delivered on Friday, emphasizes the allowance for businesses to claim tax deductions on expenses directly related to their operational endeavours, particularly in the pharmaceutical industry where legal proceedings are commonplace. This decision serves as a crucial precedent for other corporations engaged in similar litigation processes. For a comprehensive understanding of the case and its implications, access to the full documentation is available through Law360’s detailed report.